Replies to post #114429 on Biotech Values

[genisi]

GILD's elvitegravir met primary endpoint of noninferiority compared with Isentress in a phase III study 145:

http://finance.yahoo.com/news/Gilead-HIV-drug-meets-study-apf-4283405651.html?x=0&.v=1

[DewDiligence]

GILD is selling off in AH trading; the causes are:

• Reduced HIV reimbursements from the ADAP programs in TX and FL due to uncertainty regarding the US federal budget.

• Lower Tamiflu royalties from Roche due to the absence of a pandemic threat. (This should have been fully known since GILD books Tamiflu royalties from Roche with a one-quarter lag.)

• Uncollectable accounts receivable in Southern Europe.